Core Laboratories Q4 EPS Tops Estimates as Costs Rise 6.4%
Core Laboratories delivered adjusted Q4 EPS of $0.21, beating estimates and down from $0.22 a year ago, while revenues rose 7% to $138.3 million, surpassing the $132 million consensus. Total costs climbed 6.4% year-over-year, and the company repurchased $5.7 million of stock, cut net debt by $1.2 million and held its dividend at $0.01 per share.
1. Q4 Financial Results
Core Laboratories reported adjusted Q4 earnings of $0.21 per share, beating the $0.20 consensus but down from $0.22 a year earlier. Operating revenues reached $138.3 million, up 7% year-over-year and above the $132 million estimate.
2. Segment Performance
Revenues in the Reservoir Description segment increased 6.3% to $92.3 million but operating income declined to $12.8 million. Production Enhancement revenues rose 8.3% to $46 million, driving an operating profit of $3.0 million versus a $2.6 million loss last year.
3. Balance Sheet and Capital Returns
The company repurchased 363,207 shares for $5.7 million, reduced net debt by $1.2 million and lowered its debt leverage ratio to 1.09. Cash and equivalents stood at $22.8 million against $110.3 million of long-term debt, and the board declared a $0.01 per share quarterly dividend unchanged.
4. Q1 Outlook
For Q1 2026, Core Laboratories projects revenues of $124 million to $130 million and EPS of $0.11 to $0.15. First-quarter guidance reflects higher interest expense from a new $50 million term loan and anticipates softer U.S. land activity offset by increased demand for diagnostic and energetic technologies.